Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;47(6):689-701.
doi: 10.1007/s00270-024-03696-y. Epub 2024 Mar 15.

MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer

Kin Fen Kevin Fung #  1   2 , Roberto Luigi Cazzato #  3 , Thibault Tricard  4 , Pierre D E Marini  3 , Gregory Bertucci  3 , Pierre-Alexis Autrusseau  3 , Guillaume Koch  3   5 , Julia Weiss  3 , Julien Garnon  3 , Hervé Lang  4 , Afshin Gangi  3   6
Affiliations
Review

MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer

Kin Fen Kevin Fung et al. Cardiovasc Intervent Radiol. 2024 Jun.

Abstract

The optimal treatment strategy for men with localised prostatic cancer of low and intermediate risk is an actively evolving field. It is important to strike a balance between maximal oncological control and minimal treatment-related complications, which helps preserve the patients' quality of life. MR-guided transurethral ultrasound ablation (TULSA) has emerged as a minimally invasive treatment option for this group of patients. This article aims to provide of a background on TULSA technology, a step-by-step procedural guide of MR-guided TULSA and to summarise the current evidence of TULSA in management of localised prostatic cancer, as well as other potential indications.

Keywords: Ablation; Interventional oncology; Magnetic resonance; Prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. - DOI - PubMed
    1. Klotz L. Overdiagnosis in urologic cancer. World J Urol. 2022;40(1):1–8. - DOI - PubMed
    1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62. - DOI - PubMed
    1. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31. - DOI - PubMed
    1. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208(1):10–8. - DOI - PubMed

MeSH terms

LinkOut - more resources